Denmark

Genmab

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020

Lead Product(s): Tisotumab Vedotin

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 27, 2020

Details:

Results from the phase 2 innovaTV 204 study evaluating tisotumab vedotin in patients with recurrent or metastatic cervical cancer will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Oncology Venture

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Oncology Venture Acquires Full Ownership of its PARP Inhibitor (2X-121) Program

Lead Product(s): 2X-121

Therapeutic Area: Oncology Product Name: 2X-121

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: 2X Oncology

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition July 13, 2020

Details:

The Company now has 100 % ownership of 2X-121, which is being clinically developed as an anti-cancer therapeutic, as well as being tested as an anti-viral agent against COVID-19.

Genmab

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

Lead Product(s): Tisotumab Vedotin

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 29, 2020

Details:

Results from innovaTV 204 evaluating tisotumab vedotin showed that a 24 percent confirmed objective response rate (ORR) by independent central review (95% Confidence Interval: 15.9% - 33.3%) with a median duration of response (DOR) of 8.3 months.

Oncology Venture

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Oncology Venture Out-Licenses Clinical Assets to Smerud

Lead Product(s): Cisplatin

Therapeutic Area: Oncology Product Name: LiPlaCis

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Smerud Medical Research

Deal Size: $30.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement June 29, 2020

Details:

Oncology Venture has entered a definitive agreement, out-licensing two clinical pipeline assets, LiPlaCis® and 2X-111, to Smerud Medical Research International for further clinical and commercial development.

Scandion Oncology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Scandion Oncology receives DKK 5 million

Lead Product(s): SCO-101,Taxane

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: Innovation Fund Denmark

Deal Size: $0.7 million Upfront Cash: Undisclosed

Deal Type: Funding February 19, 2020

Details:

The grant of DKK 5 million from Innovation Fund Denmark is earmarked for the clinical phase II development of SCO-101 in metastatic pancreatic cancer.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Genmab

Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020

Oncology Venture

Oncology Venture Acquires Full Ownership of its PARP Inhibitor (2X-121) Program

Genmab

Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

Oncology Venture

Oncology Venture Out-Licenses Clinical Assets to Smerud

Scandion Oncology

Scandion Oncology receives DKK 5 million